Loading…
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $380M | $-5M | $-21M | $35M | -7.0% | 13.8% | -140.6% |
| 2024 | $334M | $-36M | $53M | $32M | 13.9% | 19.1% | - |
| 2023 | $280M | $-87M | $-190M | $-28M | -72.8% | -12.9% | - |
| 2022 | $322M | $-61M | $-77M | $-50M | -17.8% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 321.79 | 280.32 | 333.79 | 379.81 |
| Cost Of Revenue | 112.21 | 102.07 | 109.70 | 123.24 |
| Gross Profit | 209.58 | 178.26 | 224.09 | 256.57 |
| Operating Expense | 286.81 | 285.32 | 279.62 | 281.64 |
| Operating Income | -77.23 | -107.06 | -55.53 | -25.07 |
| EBITDA | -61.22 | -87.24 | -35.78 | -4.66 |
| EBIT | -77.23 | -107.06 | -55.53 | -25.07 |
| Pretax Income | -76.23 | -190.14 | 52.86 | -21.08 |
| Tax Provision | 0.38 | 0.14 | 0.31 | 0.27 |
| Net Income | -76.61 | -190.28 | 52.55 | -21.35 |
| Net Income Common Stockholders | -76.61 | -190.28 | 52.55 | -21.35 |
| Total Expenses | 399.02 | 387.39 | 389.32 | 404.88 |
| Interest Income | 3.76 | 11.87 | 11.77 | 9.17 |
| Research And Development | 90.39 | 82.42 | 72.51 | 71.43 |
| Selling General And Administration | 196.42 | 202.90 | 207.11 | 210.21 |
| Normalized EBITDA | -61.33 | 9.06 | -132.08 | 1.05 |
| Normalized Income | -76.70 | -114.21 | -43.17 | -16.84 |
| Basic EPS | -1.44 | -3.54 | 1 | 0 |
| Diluted EPS | -1.44 | -3.54 | 0.93 | 0 |
| Tax Effect Of Unusual Items | 0.02 | -20.22 | 0.58 | -1.20 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.01 | 0.21 |
| Total Unusual Items | 0.11 | -96.30 | 96.30 | -5.71 |
| Total Unusual Items Excluding Goodwill | 0.11 | -96.30 | 96.30 | -5.71 |
| Net Income From Continuing Operation Net Minority Interest | -76.61 | -190.28 | 52.55 | -21.35 |
| Reconciled Depreciation | 16.01 | 19.82 | 19.76 | 20.42 |
| Reconciled Cost Of Revenue | 112.21 | 102.07 | 109.70 | 123.24 |
| Net Interest Income | 3.76 | 11.87 | 11.77 | 9.17 |
| Net Income From Continuing And Discontinued Operation | -76.61 | -190.28 | 52.55 | -21.35 |
| Total Operating Income As Reported | -77.23 | -203.36 | 40.77 | -30.78 |
| Diluted Average Shares | 53.32 | 53.76 | 56.62 | 0 |
| Basic Average Shares | 53.32 | 53.76 | 52.77 | 0 |
| Diluted NI Availto Com Stockholders | -76.61 | -190.28 | 52.55 | -21.35 |
| Net Income Including Noncontrolling Interests | -76.61 | -190.28 | 52.55 | -21.35 |
| Net Income Continuous Operations | -76.61 | -190.28 | 52.55 | -21.35 |
| Other Income Expense | -2.77 | -94.95 | 96.63 | -5.19 |
| Other Non Operating Income Expenses | -2.87 | 1.35 | 0.33 | 0.52 |
| Special Income Charges | 0 | -96.30 | 96.30 | -5.71 |
| Other Special Charges | 0 | 96.30 | -96.30 | 5.71 |
| Restructuring And Mergern Acquisition | 0 | 2.32 | 1.78 | 0 |
| Gain On Sale Of Security | 0.11 | 0.01 | 0 | 0 |
| Net Non Operating Interest Income Expense | 3.76 | 11.87 | 11.77 | 9.17 |
| Interest Income Non Operating | 3.76 | 11.87 | 11.77 | 9.17 |
| Selling And Marketing Expense | 96.03 | 84.06 | 81.97 | 102.64 |
| General And Administrative Expense | 100.40 | 118.84 | 125.14 | 107.56 |
| Other Gand A | 100.40 | 118.84 | 125.14 | 107.56 |
| Operating Revenue | 321.79 | 280.32 | 333.79 | 379.81 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| CareDx, Inc.this co. | CDNA | $1.1B | - | 3.49 | -7.0% | -124.58 |
| InnovAge Holding Corp. | INNV | $1.1B | 161.40 | 4.27 | -11.5% | 25.32 |
| Zenas BioPharma, Inc. | ZBIO | $1.1B | - | - | -156.0% | -3.15 |
| EyePoint, Inc. | EYPT | $1.1B | - | 32.47 | -75.8% | -4.95 |
| Pacira BioSciences, Inc. | PCRX | $1.1B | 149.91 | 1.52 |
| 1.0% |
| 10.73 |
| Teladoc Health, Inc. | TDOC | $1.1B | - | 0.77 | -14.5% | 39.94 |
| IRADIMED CORPORATION | IRMD | $1.1B | 47.83 | 11.31 | 23.8% | 37.30 |
| The Pennant Group, Inc. | PNTG | $1.1B | 36.56 | 3.22 | 7.9% | 25.85 |
| Septerna, Inc. | SEPN | $1.1B | - | 2.75 | -12.8% | -8.66 |
| Peer Median | - | 98.87 | 3.22 | -12.2% | 18.02 | |